In last trading session, BridgeBio Pharma, Inc. (NASDAQ:BBIO) saw 847,621 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $68.61 trading at -$1.12 or -1.61% at ring of the bell on the day assigns it a market valuation of $8.42 Billion. That closing price of BBIO’s stock is at a discount of -4.71% from its 52-week high price of $71.84 and is indicating a premium of 79.26% from its 52-week low price of $14.23. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 708.85 Million shares which gives us an average trading volume of 650.56 Million if we extend that period to 3-months.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

For BridgeBio Pharma, Inc. (BBIO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.7. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 6 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.84 in the current quarter.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) trade information

In the face of being in the red during last session for losing -1.61%, in the last five days BBIO remained trading in the green while hitting it’s week-highest on Thursday, Jan 14 when the stock touched $70.01- price level, adding 2% to its value on the day. BridgeBio Pharma, Inc.’s shares saw a change of -3.52% in year-to-date performance and have moved 4.73% in past 5-day. BridgeBio Pharma, Inc. (NASDAQ:BBIO) showed a performance of 12.49% in past 30-days. Number of shares sold short was 10.75 Million shares which calculate 0.02 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $63.75 to the stock, which implies targetted prices is already lagging behind -7.08% to its current value. Analysts have been projecting $44 as a low price target for the stock while placing it at a high target of $91. It follows that stock’s current price would jump +32.63% in reaching the projected high whereas dropping to the targeted low would mean a loss of -35.87% for stock’s current value.

BridgeBio Pharma, Inc. (BBIO) estimates and forecasts

Statistics highlight that BridgeBio Pharma, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +117.6% of value to its shares in past 6 months, showing an annual growth rate of -47.58% while that of industry is -5.6. Apart from that, the company came lowering its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to decline by -35.5% in the current quarter and calculating -20.5% decline in the next quarter. This year revenue growth is estimated to drop -40.5% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $16.93 Million for the same. And 4 analysts are in estimates of company making revenue of $7.32 Million in the next quarter that will end on March 01, 2021. Company posted $13.82 Million of sales in current quarter a year earlier. Analysts are expecting this quarter sales to grow by 22.5%.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2021, company’s earnings growth rate is likely to be around -118.1% while estimates for its earnings growth in next 5 years are of 0%


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


BridgeBio Pharma, Inc. (NASDAQ:BBIO)’s Major holders

Insiders are in possession of 8.89% of company’s total shares while institution are holding 101.87% percent of that, with stock having share float percentage of 111.81%. Investors also watch the number of corporate investors in a company very closely, which is 188 institutions for BridgeBio Pharma, Inc. that are currently holding shares of the company. Kohlberg Kravis Roberts & Co. L.P. is the top institutional holder at BBIO for having 34.51 Million shares of worth $1.29 Billion. And as of September 29, 2020, it was holding 28.13% of the company’s outstanding shares.

The second largest institutional holder is Viking Global Investors, L.P., which was holding about 26.62 Million shares on September 29, 2020. The number of shares represents firm’s hold over 21.7% of outstanding shares, having a total worth of $998.82 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund are the top two Mutual Funds which own company’s shares. As of September 29, 2020, the former fund manager was holding 2059966 shares of worth $77.29 Million or 1.68% of the total outstanding shares. The later fund manager was in possession of 1.71 Million shares on September 29, 2020, making its stake of worth around $64.32 Million in the company or a holder of 1.4% of company’s stock.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on…

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
.

Sponsored


Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

LEAVE A REPLY

Please enter your comment!
Please enter your name here